Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials

Medicine
Minhua FanShihong Zhang

Abstract

Sitagliptin has been reported to improve lipid profiles, but findings from these studies are conflicting. We conducted this meta-analysis to evaluate the effects of sitagliptin on serum lipids in patients with type 2 diabetes mellitus.We made a comprehensive literature search in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and VIP database until June 2015. Eligible studies were randomized clinical trials (RCTs) that investigated the effect of sitagliptin on serum triglycerides (TGs), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or high-density lipoprotein cholesterol (HDL-C).Eleven RCTs with 2338 patients were identified. Compared with controls, sitagliptin alone or in combination significantly improved serum TG (weighted mean difference [WMD] -0.24 mmol/L; 95% confidence interval [CI] -0.40 to -0.09; P = 0.002) and HDL-C (WMD 0.05 mmol/L; 95% CI 0.02-0.07; P < 0.001).However, no statistical significances were observed in LDL-C (WMD -0.07 mmol/L; 95% CI -0.22 to 0.08; P = 0.337) and TC (WMD -0.14; 95% CI -0.33 to 0.06; P = 0.177). Subgroup analyses revealed that sitagliptin alone achieved greater improvement in serum TG, TC, and HDL-C levels.These findings suggested...Continue Reading

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 19, 2008·Diabetes, Obesity & Metabolism·R ScottUNKNOWN Sitagliptin Study 801 Group
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jul 23, 2009·Annals of Internal Medicine·David MoherUNKNOWN PRISMA Group
Aug 23, 2011·Diabetes Research and Clinical Practice·Özen ÖzSazi Imamoğlu
Jan 5, 2012·Advances in Therapy·Matteo MonamiEdoardo Mannucci
Dec 12, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·N Matikainen, M-R Taskinen
Feb 26, 2013·Cardiovascular Diabetology·Yoshiko SakamotoUNKNOWN S-DOG investigators
Mar 13, 2013·Drugs·Joe M ChehadeArshag D Mooradian
May 18, 2013·Diabetes & Metabolic Syndrome·Md N KarimLiaquat Ali
Aug 8, 2013·Expert Opinion on Pharmacotherapy·Carolyn F Deacon, Jens J Holst
Nov 19, 2013·Journal of the American College of Cardiology·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Dec 11, 2013·Current Pharmaceutical Design·Manfredi RizzoAli A Rizvi
Nov 14, 2014·The Journal of Clinical Endocrinology and Metabolism·Manfredi RizzoGiovanni Li Volti

❮ Previous
Next ❯

Citations

Jul 14, 2016·HIV Clinical Trials·Changzhong JinNanping Wu
Apr 1, 2017·Current Opinion in Cardiology·Niki KatsikiDimitri P Mikhailidis
Jan 24, 2019·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Maryam RameshradHossein Hosseinzadeh
Jun 3, 2020·Advanced Drug Delivery Reviews·Kerstin StemmerTimo D Müller

❮ Previous
Next ❯

Software Mentioned

Revman
STATA

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.